CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype ...

The medication can be taken monthly by injection and resulted in an average weight loss of up to 20% over 52 weeks, according to data released by the company. Unlike other treatments, MariTide has ...

What's especially promising is that MariTide can help people lose up to 20% of their body weight after a year, per a recent phase 2 trial. While analysts were hoping to see weight loss of up to 25 ...

Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections. But MariTide, which is Amgen's GLP-1 drug, only needs to be ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Management strongly denied that its weight loss drugs had suffered "misssteps", but personally, I am beginning to wonder if MariTide is the "real deal". While Amgen stated in November that "there ...

MariTide Phase 3 studies to begin in first half ... placed a hold on an early-stage trial of a different experimental weight-loss drug. The company's shares, which have gained more than 11% ...

(Reuters) - Amgen (NASDAQ:AMGN) posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year ...